LifeMD (NASDAQ:LFMD) Sets New 52-Week High at $12.50

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $12.50 and last traded at $12.49, with a volume of 602630 shares trading hands. The stock had previously closed at $11.64.

Analysts Set New Price Targets

A number of equities research analysts have commented on LFMD shares. BTIG Research raised their target price on shares of LifeMD from $13.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, April 23rd. HC Wainwright lifted their target price on shares of LifeMD from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, January 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, LifeMD currently has a consensus rating of "Buy" and a consensus target price of $10.40.

LifeMD Stock Up 7.3 %

The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22. The company has a 50 day simple moving average of $9.70 and a two-hundred day simple moving average of $7.87. The firm has a market capitalization of $510.72 million, a P/E ratio of -17.84 and a beta of 1.38.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its earnings results on Monday, March 11th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The company had revenue of $44.86 million for the quarter, compared to the consensus estimate of $40.65 million. On average, equities analysts predict that LifeMD, Inc. will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LFMD. Dorsey Wright & Associates bought a new position in LifeMD during the third quarter valued at approximately $37,000. Tower Research Capital LLC TRC boosted its position in shares of LifeMD by 266.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company's stock valued at $38,000 after acquiring an additional 3,348 shares during the last quarter. Worth Venture Partners LLC purchased a new position in shares of LifeMD in the third quarter valued at $64,000. Freedom Wealth Alliance LLC bought a new stake in LifeMD in the third quarter worth $68,000. Finally, Thompson Davis & CO. Inc. purchased a new stake in LifeMD during the fourth quarter valued at $117,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.